company background image
VBS

Vectus BiosystemsASX:VBS Stock Report

Market Cap

AU$47.8m

7D

2.0%

1Y

53.1%

Updated

14 Oct, 2021

Data

Company Financials
VBS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

VBS Overview

Vectus Biosystems Limited engages in the medical research and development activities in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Vectus Biosystems
Historical stock prices
Current Share PriceAU$1.50
52 Week HighAU$0.88
52 Week LowAU$1.89
Beta0.39
1 Month Change-3.85%
3 Month Change11.52%
1 Year Change53.06%
3 Year Change114.29%
5 Year Change4.17%
Change since IPO-3.23%

Recent News & Updates

Dec 31
Our Take On Vectus Biosystems' (ASX:VBS) CEO Salary

Our Take On Vectus Biosystems' (ASX:VBS) CEO Salary

The CEO of Vectus Biosystems Limited ( ASX:VBS ) is Karen Duggan, and this article examines the executive's...

Shareholder Returns

VBSAU BiotechsAU Market
7D2.0%2.0%0.1%
1Y53.1%1.2%19.3%

Return vs Industry: VBS exceeded the Australian Biotechs industry which returned -0.6% over the past year.

Return vs Market: VBS exceeded the Australian Market which returned 17.9% over the past year.

Price Volatility

Is VBS's price volatile compared to industry and market?
VBS volatility
VBS Beta0.39
Industry Beta1.61
Market Beta1

Stable Share Price: VBS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: VBS's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005n/aKaren Dugganhttps://www.vectusbiosystems.com.au

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys.

Vectus Biosystems Fundamentals Summary

How do Vectus Biosystems's earnings and revenue compare to its market cap?
VBS fundamental statistics
Market CapAU$47.81m
Earnings (TTM)-AU$4.28m
Revenue (TTM)AU$81.59k

585.9x

P/S Ratio

-11.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VBS income statement (TTM)
RevenueAU$81.59k
Cost of RevenueAU$0
Gross ProfitAU$81.59k
ExpensesAU$4.36m
Earnings-AU$4.28m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.13
Gross Margin100.00%
Net Profit Margin-5,248.89%
Debt/Equity Ratio-270.4%

How did VBS perform over the long term?

See historical performance and comparison

Valuation

Is Vectus Biosystems undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Vectus Biosystems is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Vectus Biosystems has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Vectus Biosystems forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vectus Biosystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Vectus Biosystems performed over the past 5 years?

0.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VBS is currently unprofitable.

Growing Profit Margin: VBS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VBS is unprofitable, but has reduced losses over the past 5 years at a rate of 0.3% per year.

Accelerating Growth: Unable to compare VBS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VBS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (45.9%).


Return on Equity

High ROE: VBS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Vectus Biosystems's financial position?


Financial Position Analysis

Short Term Liabilities: VBS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VBS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VBS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: VBS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VBS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VBS has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 3.2% each year.


Dividend

What is Vectus Biosystems's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VBS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VBS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VBS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VBS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VBS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average board tenure


CEO

Karen Duggan

no data

Tenure

AU$223,882

Compensation

Dr. Karen Annette Duggan serves as the Chief Executive Officer of Vectus Biosystems Limited and has been its Executive Director since September 4, 2006. Dr. Duggan is the Founder of Vectus. She was formall...


CEO Compensation Analysis

Compensation vs Market: Karen's total compensation ($USD164.92K) is below average for companies of similar size in the Australian market ($USD300.22K).

Compensation vs Earnings: Karen's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: VBS's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.7%.


Top Shareholders

Company Information

Vectus Biosystems Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Vectus Biosystems Limited
  • Ticker: VBS
  • Exchange: ASX
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$47.806m
  • Shares outstanding: 31.87m
  • Website: https://www.vectusbiosystems.com.au

Number of Employees


Location

  • Vectus Biosystems Limited
  • 3-11 Primrose Avenue
  • Rosebery
  • New South Wales
  • 2018
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/14 07:04
End of Day Share Price2021/10/12 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.